JP2020524675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524675A5 JP2020524675A5 JP2019569931A JP2019569931A JP2020524675A5 JP 2020524675 A5 JP2020524675 A5 JP 2020524675A5 JP 2019569931 A JP2019569931 A JP 2019569931A JP 2019569931 A JP2019569931 A JP 2019569931A JP 2020524675 A5 JP2020524675 A5 JP 2020524675A5
- Authority
- JP
- Japan
- Prior art keywords
- moiety
- adc
- linker
- conjugation
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LIXLFMBECHROQQ-FBLRIXIVSA-N CC(C)N(C)Cc1nc([C@@](C[C@@H](c2c(c(C(c(c3ccc4)c4OC)=O)c4C3=O)O)O[C@@H]3O[C@@H](C)[C@H]5O[C@H](COCC6)N6[C@H]5C3)(Cc2c4O)O)c[s]1 Chemical compound CC(C)N(C)Cc1nc([C@@](C[C@@H](c2c(c(C(c(c3ccc4)c4OC)=O)c4C3=O)O)O[C@@H]3O[C@@H](C)[C@H]5O[C@H](COCC6)N6[C@H]5C3)(Cc2c4O)O)c[s]1 LIXLFMBECHROQQ-FBLRIXIVSA-N 0.000 description 1
- 0 CC[C@](C)[C@@]([C@@](CC(N(CCC1)[C@@]1C([C@@](C)C(N[C@](C*)Cc1ccccc1)=O)OC)=O)OC)N(C)C([C@](C(C)C)NC([C@](C(C)C)N(C)C(C)C)=O)=O Chemical compound CC[C@](C)[C@@]([C@@](CC(N(CCC1)[C@@]1C([C@@](C)C(N[C@](C*)Cc1ccccc1)=O)OC)=O)OC)N(C)C([C@](C(C)C)NC([C@](C(C)C)N(C)C(C)C)=O)=O 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023131993A JP2023138866A (ja) | 2017-06-20 | 2023-08-14 | Ｃｄ３８抗体薬物コンジュゲート |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762522516P | 2017-06-20 | 2017-06-20 | |
| US62/522,516 | 2017-06-20 | ||
| US201762553438P | 2017-09-01 | 2017-09-01 | |
| US62/553,438 | 2017-09-01 | ||
| PCT/IB2018/054564 WO2018235024A1 (en) | 2017-06-20 | 2018-06-20 | Cd38 antibody drug conjugate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023131993A Division JP2023138866A (ja) | 2017-06-20 | 2023-08-14 | Ｃｄ３８抗体薬物コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020524675A JP2020524675A (ja) | 2020-08-20 |
| JP2020524675A5 true JP2020524675A5 (enExample) | 2021-07-29 |
| JP7359700B2 JP7359700B2 (ja) | 2023-10-11 |
Family
ID=63036271
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569931A Active JP7359700B2 (ja) | 2017-06-20 | 2018-06-20 | Ｃｄ３８抗体薬物コンジュゲート |
| JP2023131993A Pending JP2023138866A (ja) | 2017-06-20 | 2023-08-14 | Ｃｄ３８抗体薬物コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023131993A Pending JP2023138866A (ja) | 2017-06-20 | 2023-08-14 | Ｃｄ３８抗体薬物コンジュゲート |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11191845B2 (enExample) |
| EP (2) | EP4509143A3 (enExample) |
| JP (2) | JP7359700B2 (enExample) |
| KR (1) | KR102771835B1 (enExample) |
| CN (1) | CN110997009B (enExample) |
| AU (1) | AU2018288463A1 (enExample) |
| CA (1) | CA3067311A1 (enExample) |
| ES (1) | ES2996334T3 (enExample) |
| WO (1) | WO2018235024A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7637510B2 (ja) * | 2018-06-20 | 2025-02-28 | ビバソル， インコーポレイテッド | Ｃｄ３８に結合するバリアント抗体 |
| EP3636284A1 (en) * | 2018-10-11 | 2020-04-15 | NBE Therapeutics AG | Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications |
| JP7555953B2 (ja) * | 2019-03-29 | 2024-09-25 | ソレント・セラピューティクス・インコーポレイテッド | Ｃｄ３８に結合する操作されたバリアント抗体 |
| GB201908886D0 (en) * | 2019-06-20 | 2019-08-07 | Almac Discovery Ltd | Anthracycline derivatives |
| EP4241789A4 (en) * | 2020-12-08 | 2025-04-02 | Nona Biosciences (Shanghai) Co., Ltd. | Protein-drug conjugate and site-specific conjugation method |
| WO2022184082A1 (en) | 2021-03-03 | 2022-09-09 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates comprising an anti-bcma antibody |
| CN113181373B (zh) * | 2021-05-10 | 2024-03-01 | 深圳安特生物医药科技有限公司 | 一种抗体药物偶联制剂及其制备方法和应用 |
| US20240252665A1 (en) * | 2021-06-02 | 2024-08-01 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Chemical coupling linker and use thereof |
| JP2024546152A (ja) * | 2021-12-16 | 2024-12-17 | 上海宝済薬業股▲ふん▼有限公司 | 免疫グロブリン分解酵素による切断に対抗するＦｃ変異体 |
| JP2025509286A (ja) | 2022-03-10 | 2025-04-11 | ビバソル， インコーポレイテッド | 抗体－薬物コンジュゲートおよびその使用 |
| TW202400247A (zh) * | 2022-05-10 | 2024-01-01 | 美商索倫多醫療公司 | 包含抗ｆｏｌｒ１抗體之抗體藥物結合物 |
| CN116621927B (zh) * | 2023-01-09 | 2024-03-26 | 联宁（苏州）生物制药有限公司 | 带有伊喜替康和C-lock定点偶联基团的抗体偶联中间体、偶联方法及抗体偶联药物 |
| CN121985963A (zh) | 2023-04-05 | 2026-05-05 | 维硕公司 | 抗体偶联药物及其用途 |
| WO2024211236A2 (en) | 2023-04-05 | 2024-10-10 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
| WO2024211234A1 (en) | 2023-04-05 | 2024-10-10 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
| CN120981249A (zh) * | 2023-05-12 | 2025-11-18 | 四川科伦博泰生物医药股份有限公司 | 多环化合物及其制备方法和用途 |
| CN117659041A (zh) * | 2023-12-08 | 2024-03-08 | 联宁（苏州）生物制药有限公司 | 用于抗体偶联药物的氘代蒽环类毒素连接子及其合成方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2915820A1 (en) | 2004-02-06 | 2015-09-09 | MorphoSys AG | Anti-CD38 human antibodies and uses therefor |
| US20080305044A1 (en) * | 2004-11-29 | 2008-12-11 | Seattle Genetics, Inc. | Engineered Antibodies and Immunoconjugates |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| UA108598C2 (xx) | 2008-04-30 | 2015-05-25 | Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери) | |
| EP2580243B1 (en) * | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| CN104640572B (zh) * | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物，偶联方法，及其用途 |
| ES2597228T3 (es) * | 2012-06-27 | 2017-01-17 | F. Hoffmann-La Roche Ag | Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas |
| AU2013288932A1 (en) * | 2012-07-09 | 2014-12-11 | Genentech, Inc. | Immunoconjugates comprising anti - CD79b antibodies |
| CA2909952C (en) * | 2013-04-29 | 2021-10-12 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| JP2017506640A (ja) * | 2014-02-14 | 2017-03-09 | セントローズ， エルエルシー | 細胞外標的化薬物共役体 |
| JP6871858B2 (ja) * | 2015-01-28 | 2021-05-19 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 抗体薬物コンジュゲート |
| US20170224835A1 (en) * | 2015-02-06 | 2017-08-10 | Sorrento Therapeutics, Inc. | Antibody Drug Conjugates |
| CN113527495A (zh) * | 2015-04-08 | 2021-10-22 | 索伦托药业有限公司 | 与cd38结合的抗体治疗剂 |
-
2018
- 2018-06-20 JP JP2019569931A patent/JP7359700B2/ja active Active
- 2018-06-20 CA CA3067311A patent/CA3067311A1/en active Pending
- 2018-06-20 AU AU2018288463A patent/AU2018288463A1/en not_active Abandoned
- 2018-06-20 CN CN201880051692.9A patent/CN110997009B/zh active Active
- 2018-06-20 WO PCT/IB2018/054564 patent/WO2018235024A1/en not_active Ceased
- 2018-06-20 ES ES18746292T patent/ES2996334T3/es active Active
- 2018-06-20 EP EP24208209.7A patent/EP4509143A3/en active Pending
- 2018-06-20 US US16/013,828 patent/US11191845B2/en active Active
- 2018-06-20 EP EP18746292.4A patent/EP3641831B1/en active Active
- 2018-06-20 KR KR1020207001730A patent/KR102771835B1/ko active Active
-
2021
- 2021-11-03 US US17/518,375 patent/US20220118105A1/en active Pending
-
2023
- 2023-08-14 JP JP2023131993A patent/JP2023138866A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020519643A5 (enExample) | ||
| TWI851552B (zh) | 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 | |
| JP2023547323A5 (enExample) | ||
| JP2023540732A5 (enExample) | ||
| JP2019163319A5 (enExample) | ||
| JP7359700B2 (ja) | Ｃｄ３８抗体薬物コンジュゲート | |
| JPWO2020031936A5 (enExample) | ||
| AU2022209272B2 (en) | Stable modulators of gamma-c-cytokine activity | |
| JP2020534030A5 (enExample) | ||
| JP2019515646A5 (enExample) | ||
| WO2021170961A1 (fr) | Conjugués anticorps-médicament anti-cd56 et leur utilisation en thérapie | |
| CN110740754A (zh) | 一种抗间皮素抗体及其抗体药物缀合物 | |
| JP2017500018A5 (enExample) | ||
| JP2017518040A5 (enExample) | ||
| JP2022513384A5 (enExample) | ||
| JP2017518304A5 (enExample) | ||
| JP2014502955A5 (enExample) | ||
| KR20180021723A (ko) | 항체-약물 콘주게이트의 선택적 제조 방법 | |
| JP2017113019A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| JP2020506685A5 (enExample) | ||
| JP2012510280A5 (enExample) | ||
| JP2011528561A5 (enExample) | ||
| JPWO2022102695A5 (enExample) | ||
| JP2021520393A5 (enExample) |